Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Guangzhou Binding Technologies Co. Limited maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This workload is handled by 1 distinct examiner operating within 1 distinct art unit. This structure indicates that the company's active intellectual property is currently confined to a specific sub-discipline within the Biotechnology & Pharmaceuticals field. The presence of 1 pending office action suggests a targeted approach to prosecution at this stage.
CHANDRA, GYAN is the busiest examiner for the portfolio, overseeing 1 busiest examiner pending office action. Since there is 1 pending office action in total for the Biotechnology & Pharmaceuticals sector, this examiner manages all active proceedings. Practitioners should note that the current progress of the portfolio relies on this interaction within the 1 distinct art unit. The examiner's individual interpretations of the claims will be the primary factor in the company's immediate patenting success, as there are no other active matters to provide alternative outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18217257 | Affinity Chromatography Ligands with Mild Elution pH | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18217257 | Affinity Chromatography Ligands with Mild Elution pH | CHANDRA, GYAN | 1653 | §103DP | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuangzhou Binding Technologies Co. Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gyan Chandra has the most, with 1 of Guangzhou Binding Technologies Co. Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
